實驗要點及說明:
1.本方法適用于貼壁細胞培養,而不適用于懸浮細胞培養,懸浮細胞可使用滴片法;
2.所使用的蓋玻片應該為玻璃**,并經過鉻酸洗液處理;
3.蓋玻片非常薄,易碎,取放蓋玻片時動作要輕;
4.如果需要更多生長狀態一致的細胞,可以使用較大的培養皿,但不宜過大,以避免培養液的浪費和增加污染機率;
5.如果細胞貼壁生長能力較差,可將蓋玻片在0.5%多聚賴氨酸溶液中浸泡5-10分鐘并自然晾干。
產品名稱
規格
貨號
小鼠胚胎成纖維細胞
1×106
BH-X019677
培養方法
傳代方法 將舊培養液吸除,PBS清洗兩遍后,加入6mL(/100mm皿)胰酶,在顯微鏡下觀察,期間禁止搖晃培養皿,細胞剛有脫落時,則吸除大部分胰酶,留約0.5mL,移至培養箱消化,約2min取出。傳代用12mL CM1-1培養液終止消化,輕輕吹打均勻細胞,后可分3~6皿培養;
生長條件 37℃,5%CO2,CM1-1培養液。CM1-1培養液:90%DMEM-H+10%FBS。DMEM-H:DMEM高糖培養液,含谷氨酰胺,含丙酮酸鈉。
存儲條件 ???存則用6mL凍存液(90%FBS+10%DMSO)終止消化,吹打均勻,分為6支凍存管,用程序降溫盒于-80℃凍存,過夜轉移至液氮中保存。
我司常期代理ATCC Acris abcam cst Biorbyt santa Novus sigma lifespan NEB roche ABI R&D millipore BD Qiagen Cayman Jackson Life GeneTex Bio-Rad DSHB tocris peprotech 等品牌;部分產品現貨,超低比價,貨期短,價格優,公司產品僅用于科研售后齊全。
培養操作步驟 :
1.用蓋片鑷將蓋玻片自75%乙醇中取出,用無菌絲綢布擦拭干凈,不要用紗布;
2.將蓋玻片輕輕放入6孔培養板(每孔一片)或培養皿中(每個平皿可放置2-3片);
3.在距離紫外燈直射范圍內20-30 厘米處照射2-3小時;
4.將經過計數的細胞懸浮液移入培養板中,使蓋玻片完全浸在培養液中;
5.將培養板在5% CO2水浴孵箱中37℃孵育2-3天,當貼壁細胞生長至覆蓋培養板底部2/3面積時,將培養板取出,用蓋片鑷輕輕取出蓋玻片,用蒸餾水漂洗后即可進行快速固定以及細胞化學檢測。
1、細胞傳代:細胞密度達到80-90%時即可傳代
①棄去培養上清,用PBS或生理鹽水清洗1-2次;
②加入2ml0.25%胰酶(T25瓶),使胰酶覆蓋整個瓶或皿,蓋好放入培養箱消化;
③1-2min后,顯微鏡下觀察細胞,若大部分細胞回縮且有少量細胞脫落,輕輕吹打下確認消化情況后加入完全培養基終止消化;若細胞還是貼壁,放回培養箱繼續消化至可以輕輕吹打下為止;
④將細胞懸液1000RPM左右條件下離心4min,棄上清;
⑤用新鮮培養基重懸后加入培養瓶或皿中,T25培養瓶加6-8ml培養基;
⑥懸浮細胞直接離心收集,細胞沉淀重懸后分到新培養瓶中。
2、細胞復蘇:
①將凍存管在37℃溫水中快速搖晃融化,時間1min左右,加入4-5ml培養基混勻。
②在1000RPM左右條件下離心4min,棄上清,加1-2ml培養基吹勻,將細胞懸液加入培養瓶中,補加適量培養基。
3、細胞凍存:待細胞生長狀態良好時進行細胞凍存保種
①棄去培養上清,用PBS或生理鹽水清洗1-2次,加入1mL 0.25%胰蛋白酶(T25瓶)
②1-2min后,顯微鏡下觀察細胞,大部分細胞回縮且有少量細胞脫落,輕輕吹打下確認消化情況后加入完全培養基終止消化;
③將細胞懸液1000RPM左右條件下離心4min,棄上清,加1ml凍存液重懸細胞;
④將凍存管放入程序降溫盒,放入-80℃冰箱,4小時后將凍存管轉入液氮罐儲存。
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產品介紹 OSTM1 (osteopetrosis associated transmembrane protein 1), also known as gl (gray-lethal) or HSPC019, is a 338 amino acid single-pass type I membrane protein that is expressed primarily in osteoclasts and melanocytes as well as brain, kidney and spleen. Bone autosomal recessive osteopetrosis (ARO) is the most severe form of hereditary bone disease whose cellular basis is in the osteoclast and is characterized by abnormally dense bone, due to defective resorption of immature bone. ARO is suggested to be caused by mutations in the OSTM1 gene. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or *****hood. Defects in the OSTM1 gene are also the cause of the spontaneous gl mutant, which is responsible for a coat color defect in mice.
Subcellular Location : Membrane; Single-pass type I membrane protein.
[DISEASE] Defects in OSTM1 are the cause of osteopetrosis autosomal recessive type 5 (OPTB5) ; also called infantile malignant osteopetrosis 3. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or *****hood. OPTB5 patients manifest primary central nervous system involvement in addition to the classical stigmata of severe bone sclerosis, growth failure, anemia, thrombocytopenia and visual impairment with optic atrophy.
英文名稱 Anti-OCEL1
中文名稱 緊密連接蛋白/小分子膠原蛋白OCEL1抗體
別 名 Occludin/ELL domain containing 1; Occludin/ELL domain containing protein 1; OCEL1_HUMAN.
濃 度 1mg/1ml
規 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應 Human, Mouse, Rat, Pig, Cow, Sheep
產品類型 一抗
研究領域 細胞生物 細胞膜受體
蛋白分子量 predicted molecular weight: 29kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human OCEL1
亞 型 IgG
接觸蛋白1檢測試劑盒氧化銠,水合 銠 55%肉桂 97%
結腸癌抗原檢測試劑盒氯亞鉑酸鈉 Pt 44.5%己 97%
結蛋白檢測試劑盒四氯鈀酸鈉 98%正己 standard for GC, ≥99.0% (GC)
結締組織生長因子檢測試劑盒六氯代鉑酸鈉六水合物 Pt 34.0%己 ≥97%, FCC, Kosher, FG
結合珠蛋白檢測試劑盒氯金酸鈉 金含量,48% 香茅 85%,FCC
結核桿菌IgG抗體檢測試劑盒硫酸銠溶液 80g(Rh)/L水溶液肉桂 98%

細胞培養方法:
小鼠胚胎成纖維細胞窖蛋白Caveolin1檢測試劑盒銠粉 99.99% metals basis2-環戊基環戊酮 97%
- 溫馨提示:為規避購買風險,建議您在購買前務必確認供應商資質與產品質量。
- 免責申明:以上內容為注冊會員自行發布,若信息的真實性、合法性存在爭議,平臺將會監督協助處理,歡迎舉報


